Literature DB >> 9298542

Involvement of cyclic nucleotide-dependent protein kinases in cyclic AMP-mediated vasorelaxation.

A Eckly-Michel1, V Martin, C Lugnier.   

Abstract

1. The involvement of cyclic AMP-dependent protein kinase (PKA) and cyclic GMP-dependent protein kinase (PKC) in the effects of cyclic AMP-elevating agents on vascular smooth muscle relaxation, cyclic nucleotide dependent-protein kinase activities and ATP-induced calcium signalling ([Ca2+]i was studied in rat aorta. Cyclic AMP-elevating agents used were a beta-adrenoceptor agonist (isoprenaline), a phosphodiesterase 3 (PDE3) inhibitor (SK&F 94120) and a PDE4 inhibitor (rolipram). 2. In rat intact aorta, the relaxant effect induced by isoprenaline (0.01-0.03 microM) was decreased by a specific inhibitor of PKA, H-89, whereas a specific inhibitor of PKG, Rp-8-Br-cyclic GMPs, was without effect. NO significant difference in PKA and PKG activity ratios was detected in aortic rings when isoprenaline 10 microM was used. At the same concentration, isoprenaline did not modify ATP-induced changes in [Ca2+]i in smooth muscle cells. Neither H-89 nor Rp-8-Br-cyclic GMPs modified this response. These findings suggest that PKA is only involved in the relaxant effect induced by low concentrations of isoprenaline (0.01-0.3 microM), whereas for higher concentrations, other mechanisms independent of PKA and PKG were involved. 3. The relaxant effects induced by SK&F 94120 and rolipram were inhibited by Rp-8-Br-cyclic GMPS with no significant effect of H-89. Neither SK&F 94120, nor rolipram at 30 microM significantly modified the activity ratios of PKA and PKG. Rolipram inhibited the ATP-induced transient increase in [Ca2+]i. This decrease was abolished by Rp-8-Br-cyclic GMPS whereas H-89 had no significant effect. These results suggests that PKG is involved in the vascular effects induced by the inhibitors of PDE3 and PDE4. Moreover, since it was previously shown that PDE3 and PDE4 inhibitors only increased cyclic AMP levels with no change in cyclic GMP level, these data also suggest a cross-activation of PKG by cyclic AMP in rat aorta. 4. The combinations of 5 microM SK&F 94120 with rolipram markedly potentiated the relaxant effect of rolipram. This relaxation was decreased by H-89 and not significantly modified by Rp-8-Br-cyclic GMPS. Moreover, the association of the two PDE inhibitors significantly increased the activity ratio of PKA without changing the PKG ratio. The present findings show that PKA rather than PKG is involved in this type of vasorelaxation. The differences in the participation of PKA vs PKG observed when inhibitors of PDE3 and PDE4 were used alone or together could be due to differences in the degree of accumulation of cyclic AMP, resulting in the activation of PKA or PKG which are differently localized in the cell. 5. These findings support for both PKA and PKG in cyclic AMP-mediated relaxation in raT aorta. Their involvement depends on the cellular pathway used to increase the cyclic AMP level.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9298542      PMCID: PMC1564898          DOI: 10.1038/sj.bjp.0701339

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

1.  Effect of olprinone, a phosphodiesterase III inhibitor, on arterial wall distensibility: differentiation between aorta and common carotid artery.

Authors:  M Seki; K Mizushige; T Ueda; M Kitadai; H Matsuo
Journal:  Heart Vessels       Date:  1999       Impact factor: 2.037

Review 2.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Activators of Epac proteins induce relaxation of isolated rat aorta.

Authors:  I F Sukhanova; L M Kozhevnikova; E G Popov; O N Podmareva; P V Avdonin
Journal:  Dokl Biol Sci       Date:  2006 Nov-Dec

4.  Bronchodilator and anti-inflammatory activities of glaucine: In vitro studies in human airway smooth muscle and polymorphonuclear leukocytes.

Authors:  J Cortijo; V Villagrasa; R Pons; L Berto; M Martí-Cabrera; M Martinez-Losa; T Domenech; J Beleta; E J Morcillo
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

5.  Study of the mechanisms involved in the vasorelaxation induced by (-)-epigallocatechin-3-gallate in rat aorta.

Authors:  Ezequiel Alvarez; Manuel Campos-Toimil; Hélène Justiniano-Basaran; Claire Lugnier; Francisco Orallo
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

6.  Comparative study of the vasorelaxant activity, superoxide-scavenging ability and cyclic nucleotide phosphodiesterase-inhibitory effects of hesperetin and hesperidin.

Authors:  Francisco Orallo; Ezequiel Alvarez; Hélène Basaran; Claire Lugnier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-11-17       Impact factor: 3.000

Review 7.  Cyclic nucleotide-dependent relaxation pathways in vascular smooth muscle.

Authors:  Manuel Morgado; Elisa Cairrão; António José Santos-Silva; Ignacio Verde
Journal:  Cell Mol Life Sci       Date:  2011-09-27       Impact factor: 9.261

8.  Alteration of vascular reactivity in heart failure: role of phosphodiesterases 3 and 4.

Authors:  F Hubert; M Belacel-Ouari; B Manoury; K Zhai; V Domergue-Dupont; P Mateo; F Joubert; R Fischmeister; V Leblais
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

9.  Forskolin Changes the Relationship between Cytosolic Ca and Contraction in Guinea Pig Ileum.

Authors:  Koon Hee Han; Gap Jin Cheon; Dong Soo Yeon; Seong Chun Kwon
Journal:  Korean J Physiol Pharmacol       Date:  2009-06-30       Impact factor: 2.016

10.  Changes in the vascular beta-adrenoceptor-activated signalling pathway in 2Kidney-1Clip hypertensive rats.

Authors:  Glaucia E Callera; Ester Yeh; Rita C A Tostes; Luciana C Caperuto; Carla R O Carvalho; Lusiane M Bendhack
Journal:  Br J Pharmacol       Date:  2004-03-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.